through glycan engineering.
Our mission
The next generation of therapeutics.
Kyron.bio unlocks superior protein therapeutics by harnessing the power of glycan modifications.
Our novel engineering strategy precisely controls glycosylation patterns, opening a new era of antibody therapeutics.
This has the power to deliver better therapies and transform patient outcomes.
Our people
are dedicated to revolutionising the way we make therapeutic drugs
TEAM & ADVISORS
Dr. Emilia McLaughlin
CEO & FOUNDER
Dr. Marina Lochhead
SENIOR SCIENTIST
Dr. René Labatut
VP SANOFI
Prof. Michael Ferguson
HEAD DRUG DISCOVERY UNIVERSITY OF DUNDEE
Bjørn Voldborg
HEAD NATIONAL BIOLOGICS DTU
Marie Moores
INDUSTRY ADVISOR
Dr. Damien Toullec
LAB MANAGER & TECHNICIAN
Marine Daou
FOUNDER'S ASSOCIATE
Sabine Da Silva
EXECUTIVE ASSISTANT
Proudly supported by
We would love to hear from you
and leading angel investors.